Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 8 Stomach Neoplasms 5 Triple Negative Breast Neoplasms 3 Liver Neoplasms 3 Breast Neoplasms 3 Small Cell Lung Carcinoma 2 Nasopharyngeal Carcinoma 2 Gastrointestinal Stromal Tumors 2 Esophageal Squamous Cell Carcinoma 2 Cholangiocarcinoma 2 Biliary Tract Neoplasms 2 Adrenocortical Carcinoma 2 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Cancer Limited Stage 1 Small Cell Lung Cancer Extensive Stage 1 Sarcoma 1 Salivary Gland Neoplasms 1 SCLC 1 Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neuroblastoma 1 Neoplasm Metastasis 1 Meningioma 1 Melanoma 1 Malignant Neoplasms of Digestive Organs 1 Locally Advanced Thyroid Gland Carcinoma 1 Immunotherapy Gastrict Cancer 1 HER2-negative Breast Cancer Brain Metastases 1 Gestational Trophoblastic Disease 1

Interventions

atezolizumab 1 apatinib 1 Immune Checkpoint Inhibitors 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × SCLC × apatinib × Clear all

NCT06475209 2024-06-26

Adebrelimab + Apatinib in SCLC Maintenance Therapy

Tang-Du Hospital

Phase 2 Recruiting

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡